TSPO and myeloid sarcoma: As reviewed by Airas et al., PET radioligands targeting the 18 kDa translocator protein (TSPO) can detect diffuse microglial inflammation beyond focal lesions; notably, TSPO signal intensifies during progressive phases of MS and may serve to monitor treatment efficacy in clinical trials [782, 783].